In nausea management, NK1 receptor antagonists are typically reserved for which situation?

Study for ELNEC 4: Symptom Management in Palliative Care Test with flashcards and multiple choice questions. Hints and explanations included! Get ready for your exam!

NK1 receptor antagonists work by blocking substance P at neurokinin-1 receptors in the brain, adding a distinct antiemetic mechanism to the usual serotonin and dopamine pathways. They’re most useful when nausea and vomiting do not respond to first-line agents like 5-HT3 antagonists or dopamine antagonists, making them a rescue or second-line option. This is especially important for persistent or delayed emesis, where standard regimens may fail. In palliative care, that translates to reserving NK1 antagonists for refractory cases after initial therapies have not achieved adequate control. They’re not typically first-line for all nausea, and they’re not primarily for motion sickness—that scenario is usually managed with antihistamines and anticholinergics. In practice, an NK1 antagonist may be added to a regimen after others have failed, often alongside a dexamethasone and a 5-HT3 antagonist for improved relief.